These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34056898)

  • 21. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
    Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity.
    Hu Z; Li Y; Xie B; Ning W; Xiao Y; Huang Y; Zhao C; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2019 Nov; 182():111605. PubMed ID: 31437778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
    He M; Ning W; Hu Z; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2020 Jun; 195():112281. PubMed ID: 32283297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3
    El-Ahmad Y; Tabart M; Halley F; Certal V; Thompson F; Filoche-Rommé B; Gruss-Leleu F; Muller C; Brollo M; Fabien L; Loyau V; Bertin L; Richepin P; Pilorge F; Desmazeau P; Girardet C; Beccari S; Louboutin A; Lebourg G; Le-Roux J; Terrier C; Vallée F; Steier V; Mathieu M; Rak A; Abecassis PY; Vicat P; Benard T; Bouaboula M; Sun F; Shomali M; Hebert A; Levit M; Cheng H; Courjaud A; Ginesty C; Perrault C; Garcia-Echeverria C; McCort G; Schio L
    J Med Chem; 2020 Jan; 63(2):512-528. PubMed ID: 31721572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
    Weir HM; Bradbury RH; Lawson M; Rabow AA; Buttar D; Callis RJ; Curwen JO; de Almeida C; Ballard P; Hulse M; Donald CS; Feron LJ; Karoutchi G; MacFaul P; Moss T; Norman RA; Pearson SE; Tonge M; Davies G; Walker GE; Wilson Z; Rowlinson R; Powell S; Sadler C; Richmond G; Ladd B; Pazolli E; Mazzola AM; D'Cruz C; De Savi C
    Cancer Res; 2016 Jun; 76(11):3307-18. PubMed ID: 27020862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
    Scott JS; Stead D; Barlaam B; Breed J; Carbajo RJ; Chiarparin E; Cureton N; Davey PRJ; Fisher DI; Gangl ET; Grebe T; Greenwood RD; Hande S; Hatoum-Mokdad H; Hughes SJ; Hunt TA; Johnson T; Kavanagh SL; Klinowska TCM; Larner CJB; Lawson M; Lister AS; Longmire D; Marden S; McGuire TM; McMillan C; McMurray L; Morrow CJ; Nissink JWM; Moss TA; O'Donovan DH; Polanski R; Stokes S; Thakur K; Trueman D; Truman C; Tucker MJ; Wang H; Whalley N; Wu D; Wu Y; Yang B; Yang W
    J Med Chem; 2023 Feb; 66(4):2918-2945. PubMed ID: 36727211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
    Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
    Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.
    Deng X; Deng X; Ning W; Xin L; Li Q; Hu Z; Xie B; Liang K; Min C; Dong C; Huang J; Zhou HB
    J Med Chem; 2023 Aug; 66(16):11094-11117. PubMed ID: 37584263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα
    Puyang X; Furman C; Zheng GZ; Wu ZJ; Banka D; Aithal K; Agoulnik S; Bolduc DM; Buonamici S; Caleb B; Das S; Eckley S; Fekkes P; Hao MH; Hart A; Houtman R; Irwin S; Joshi JJ; Karr C; Kim A; Kumar N; Kumar P; Kuznetsov G; Lai WG; Larsen N; Mackenzie C; Martin LA; Melchers D; Moriarty A; Nguyen TV; Norris J; O'Shea M; Pancholi S; Prajapati S; Rajagopalan S; Reynolds DJ; Rimkunas V; Rioux N; Ribas R; Siu A; Sivakumar S; Subramanian V; Thomas M; Vaillancourt FH; Wang J; Wardell S; Wick MJ; Yao S; Yu L; Warmuth M; Smith PG; Zhu P; Korpal M
    Cancer Discov; 2018 Sep; 8(9):1176-1193. PubMed ID: 29991605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
    Scott JS; Moss TA; Balazs A; Barlaam B; Breed J; Carbajo RJ; Chiarparin E; Davey PRJ; Delpuech O; Fawell S; Fisher DI; Gagrica S; Gangl ET; Grebe T; Greenwood RD; Hande S; Hatoum-Mokdad H; Herlihy K; Hughes S; Hunt TA; Huynh H; Janbon SLM; Johnson T; Kavanagh S; Klinowska T; Lawson M; Lister AS; Marden S; McGinnity DF; Morrow CJ; Nissink JWM; O'Donovan DH; Peng B; Polanski R; Stead DS; Stokes S; Thakur K; Throner SR; Tucker MJ; Varnes J; Wang H; Wilson DM; Wu D; Wu Y; Yang B; Yang W
    J Med Chem; 2020 Dec; 63(23):14530-14559. PubMed ID: 32910656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
    Garner F; Shomali M; Paquin D; Lyttle CR; Hattersley G
    Anticancer Drugs; 2015 Oct; 26(9):948-56. PubMed ID: 26164151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
    Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
    J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen and Fulvestrant Hybrids Showed Potency as Selective Estrogen Receptor Down-Regulators.
    Shoda T; Kato M; Fujisato T; Demizu Y; Inoue H; Naito M; Kurihara M
    Med Chem; 2017; 13(3):206-213. PubMed ID: 27494098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
    Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
    Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Designer interface peptide grafts target estrogen receptor alpha dimerization.
    Chakraborty S; Asare BK; Biswas PK; Rajnarayanan RV
    Biochem Biophys Res Commun; 2016 Sep; 478(1):116-122. PubMed ID: 27462021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
    Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
    Elife; 2022 May; 11():. PubMed ID: 35575456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of novel quinoline scaffold selective estrogen receptor degraders (SERDs) for treatment of ER positive breast cancer with enhanced antiproliferative bioactivity through immunogenic cell death (ICD) effects.
    Lu Y; Liang Z; Liu L; Zhou Y; Liu C; Zhao Z; Zheng T; Du Q; Liu W
    Eur J Med Chem; 2024 Sep; 275():116534. PubMed ID: 38870830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
    Govek SP; Nagasawa JY; Douglas KL; Lai AG; Kahraman M; Bonnefous C; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5163-7. PubMed ID: 26463130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.
    Zhang B; Kiefer JR; Blake RA; Chang JH; Hartman S; Ingalla ER; Kleinheinz T; Mody V; Nannini M; Ortwine DF; Ran Y; Sambrone A; Sampath D; Vinogradova M; Zhong Y; Nwachukwu JC; Nettles KW; Lai T; Liao J; Zheng X; Chen H; Wang X; Liang J
    Bioorg Med Chem Lett; 2019 Apr; 29(7):905-911. PubMed ID: 30732944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.